Finance, Grants, Deals

AstraZeneca Plc has completed the sale of its largest research facility at Alderley Park in Cheshire UK to Manchester Science Parks, a public-private enterprise, for an undisclosed amount.

Privately-funded Glycotope GmbH of Germany has raised €55 million in additional equity from its investors in order to complete proof-of-concept studies of two antibody therapeutics for cancer that have been developed using glycosylation technology.

Lombard Medical Technologies Plc, a medical device company which is delisting its shares in London and offering them in the United States via a Cayman Islands holding company, reported a 13% increase in 2013 revenues to $7 million and a 52.7% increase in its operating loss to $20 million.

Life Science Partners (LSP) of Amsterdam, the Netherlands has announced the closing of a new fund that will invest in companies with marketable products in the areas of medical technology, diagnostics and e-health. The fund has raised €112 million from private investors.

Verona Pharma Plc, which develops medicines for respiratory diseases, has announced a share placement, subscription, and open offer with the intention of raising up to £14 million before expenses. The funds will be used to develop a compound for COPD.

Oxford Gene Technology Ltd, which provides equipment for genetics research, has acquired Cytocell Ltd, a Cambridge, UK-based supplier of probes for detecting DNA sequences called fluorescence in situ hybridisation or FISH. Financial terms were not disclosed.

Advanced Accelerator Applications SA, a French manufacturer of nuclear medicine products, is set to acquire Imaging Equipment Ltd, a privately-held UK distributor of nuclear medicine supplies, including products made by AAA.

Transgene SA, a French company specialising in oncolytic virus therapies, plans to raise €45.5 million with a partially underwritten equity offering on the Euronext Paris stock exchange. The company is offering 4,553,551 new ordinary shares at €10 per share.

Bavarian Nordic A/S has secured a new contract with an agency of the US government for its vaccine technology, this time with the Defense Threat Reduction Agency (DTRA), part of the Department of Defense.

Roche has entered into a collaboration with a two-year old UK company, Discuva Ltd, to discover and develop new antibiotics to treat infections caused by multi-drug resistant Gram-negative bacteria – the most difficult-to-treat bacteria.